Correlation Between Climb Bio and Dogwood Therapeutics,

Can any of the company-specific risk be diversified away by investing in both Climb Bio and Dogwood Therapeutics, at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Climb Bio and Dogwood Therapeutics, into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Climb Bio and Dogwood Therapeutics,, you can compare the effects of market volatilities on Climb Bio and Dogwood Therapeutics, and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Climb Bio with a short position of Dogwood Therapeutics,. Check out your portfolio center. Please also check ongoing floating volatility patterns of Climb Bio and Dogwood Therapeutics,.

Diversification Opportunities for Climb Bio and Dogwood Therapeutics,

0.71

Correlation Coefficient

Climb Bio  Dogwood Therapeutics,

Poor diversification

The 3 months correlation between Climb and Dogwood is 0.71. Overlapping area represents the amount of risk that can be diversified away by holding Climb Bio and Dogwood Therapeutics, in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Dogwood Therapeutics, and Climb Bio is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Climb Bio are associated (or correlated) with Dogwood Therapeutics,. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Dogwood Therapeutics, has no effect on the direction of Climb Bio i.e., Climb Bio and Dogwood Therapeutics, go up and down completely randomly.

Pair Corralation between Climb Bio and Dogwood Therapeutics,

Given the investment horizon of 90 days Climb Bio is expected to under-perform the Dogwood Therapeutics,. But the stock apears to be less risky and, when comparing its historical volatility, Climb Bio is 1.98 times less risky than Dogwood Therapeutics,. The stock trades about -0.23 of its potential returns per unit of risk. The Dogwood Therapeutics, is currently generating about -0.04 of returns per unit of risk over similar time horizon. If you would invest  435.00  in Dogwood Therapeutics, on October 1, 2024 and sell it today you would lose (153.00) from holding Dogwood Therapeutics, or give up 35.17% of portfolio value over 90 days.

Time Period	3 Months [change]
Direction	Moves Together
Strength	Significant
Accuracy	97.62%
Values	Daily Returns

Climb Bio  vs.  Dogwood Therapeutics,

Climb Bio

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Climb Bio has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's basic indicators remain very healthy which may send shares a bit higher in January 2025. The recent disarray may also be a sign of long period up-swing for the firm investors.

Dogwood Therapeutics,

Risk-Adjusted Performance

1 of 100

Very Weak

Compared to the overall equity markets, risk-adjusted returns on investments in Dogwood Therapeutics, are ranked lower than 1 (%) of all global equities and portfolios over the last 90 days. In spite of fairly weak basic indicators, Dogwood Therapeutics, may actually be approaching a critical reversion point that can send shares even higher in January 2025.

Pair Trading with Climb Bio and Dogwood Therapeutics,

The main advantage of trading using opposite Climb Bio and Dogwood Therapeutics, positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Climb Bio position performs unexpectedly, Dogwood Therapeutics, can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Dogwood Therapeutics, will offset losses from the drop in Dogwood Therapeutics,'s long position.

The idea behind Climb Bio and Dogwood Therapeutics, pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Center module to all portfolio management and optimization tools to improve performance of your portfolios.